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Chronic liver disease increased the risk of severe coronavirus disease 2019 (COVID- 19). Trials to assess efficacy/safety of 
COVID- 19 vaccines in liver disease are underway. We evaluated the humoral immune response and safety of anti– COVID- 19 
vaccination among patients waiting liver transplantation (LT). We enrolled all pre- LT adults who completed anti- COVID- 19 
vaccination between January 2021- August 2021 as study group. Patients with histories of COVID- 19 received 1 vaccine dose, 
and all others received 2 doses. Patients were tested for COVID- 19 immunoglobulin G (IgG) within 1 and 2 months after vac-
cination. Safety was evaluated with telephone interviews/outpatient visits. A control group of 30 healthcare workers who under-
went vaccination in January 2021 and tested for IgG after 4 months was included. In the 89 pre- LT patients, at T1 (23 days after 
vaccination), seroconversion rate was 94.4%, and median IgG value was 1980 binding antibody units/mL (interquartile range 
646- 2080), and at T2 (68 days after vaccination) was 92.0%, with IgG value of 1450 (577- 2080); (T1 versus T2, P = 0.38). In 
the 10/89 patients who received 1 vaccine dose, the median IgG value was 274 (68- 548) before vaccine (T0), 2080 (1165- 2080) at 
T1, and 2030 (964- 2080) at T2 (T0 versus T1, P = 0.03; T1 versus T2, P = 0.99). All controls tested positive at 4 months after 
vaccination, with a median value of 847 (509- 1165; P < 0.001 versus T1 and P = 0.04 versus T2 in the study group). No serious 
adverse event was reported in both groups. Our data from 89 pre- LT patients suggest a high rate of immunization (94.4%) after 
a median time of 23 days from safe COVID- 19 vaccine. None of the patients developed COVID- 19.
Liver Transplantation 0 1‒8 2021 AASLD.
Received July 14, 2021; accepted September 20, 2021.
Patients affected by chronic liver disease (CLD) have 
well- recognized deficiencies in innate and humoral 
immunity, the so- called immune dysfunction, which 
predisposes to infections.(1,2) With the rapid spread 
of severe acute respiratory syndrome coronavirus 2 
(SARS- CoV- 2), significant concerns have been raised 
regarding patients with liver impairment. Coronavirus 
disease 2019 (COVID- 19) is a multisystem condition 
caused by SARS- CoV- 2, and the pathogenesis of liver 
involvement includes viral cytotoxicity, ischemic fail-
ure attributed to vascular endotheliitis and secondary 
to immune dysregulation or drug- induced injury.(3,4) 
A total of 2 meta- analyses(5,6) described an increased 
risk of severe COVID- 19 infection, decompensation, 
and mortality in patients with CLD, and according 
to a UK survey(7) of more than 17 million patients, 
COVID- 19 infection was associated with twice an 
increased risk of mortality with CLD. In particular, 
the presence of cirrhosis was found to be an inde-
pendent predictor of mortality in COVID- 19 infec-
tion, and large registries reported a fatality rate up to 
38.0%, which may be as high as 70.0% in decompen-
sated cirrhosis.(8,9) In patients with CLD, the defi-
ciency of innate and adaptive immune system and 
comorbidities (ie, diabetes mellitus, obesity, steato-
hepatitis, chronic kidney disease) predispose to the 
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impaired immunological responses seen with existing 
vaccination.(10) According to current literature, there 
is no confirmed information on the immunogenicity 
and safety of novel COVID- 19 vaccines in patients 
with CLD with or without hepatocellular carcinoma 
(HCC).(11,12) Nevertheless, without data suggest-
ing harm, the American Association for the Study 
of Liver and the European Association for the Study 
of the Liver currently recommend the vaccination 
against SARS- CoV- 2.(13,14) Trials to assess the effi-
cacy and safety of COVID- 19 vaccines are underway, 
but data on COVID- 19 vaccination in patients with 
liver disease are eagerly awaited.
Our working hypothesis is that patients affected 
by CLD will have an attenuated immune response 
to SARS- CoV- 2 vaccination and a third vaccination 
dose might be necessary to improve the seroconver-
sion rate, as has been reported in solid organ trans-
plant recipients.(15,16) In this study, we evaluated the 
humoral immune response and safety of messenger 
RNA (mRNA) anti- SARS- CoV- 2 vaccination among 




The enrollment period was from January 1, 2021, to 
August 5, 2021. The follow- up was closed on August 
31, 2021.
stUDY prOtOcOl
According to the National Health Institute, since 
January 2021, health care workers in Italy were allowed 
to undergo anti- SARS- CoV- 2 vaccination, and start-
ing from March 2021, prioritized vaccination was 
launched for patients on the transplant waiting list. 
Mask wearing indoors and physical distancing mea-
sures were recommended for all participants, irrespec-
tive of their vaccination status.
The participants with a previous documented 
history of COVID- 19 infection received a single 
intramuscular dose of 30 mcg of the mRNA vac-
cine Comirnaty (Pfizer- BioNTech, New York, NY) 
within 6 months after infection. All other participants 
received 2 intramuscular doses of 30 mcg Comirnaty 
or 100 mcg of the Moderna (Cambridge, MA) 
COVID- 19 mRNA vaccine, administered 21 and 
28 days apart, respectively.
In our tertiary hospital, occupational medicine in 
collaboration with the microbiology unit offered the 
opportunity to health care workers to test anti- SARS- 
CoV- 2 IgG antibodies at 4 months after vaccination. 
We collected, as a control group, 30 healthy med-
ical doctors of our hospital who underwent vaccina-
tion in January 2021 and tested antibodies 4 months 
later, without personal or family members’ history of 
COVID- 19, and without major comorbidities (arterial 
hypertension, renal insufficiency, cancers, autoimmune 
disease, etc.).
We enrolled all of the patients awaiting LT in our 
center who completed anti- SARS- CoV- 2 vaccination 
during the enrollment period and reached at least the 
1- week follow- up as a study group. All of the char-
acteristics of the LT candidates were collected as 
reported in Table  1. Estimated glomerular filtration 
rate (eGFR) was calculated with the Cockcroft- Gault 
equation.
Patients with previous COVID- 19 infection were 
tested for SARS- CoV- 2 IgG antibodies before vac-
cination. All participants were tested within 1 month 
(T1) and 2 months (T2) after the completion of the 
vaccine schedule.
Safety in pre- LT patients was evaluated with weekly 
telephone interviews and outpatient visits, if neces-
sary, until 21 days after the second dose and at least 
1 planned outpatient visit at 1 month after the second 
dose.
No organs from executed prisoners were used. 
According to Italian law, regional transplantation cen-
ters are the custodians of recipient/donor biomedical 
data for research purposes. All study procedures com-
ply with the ethical standards of the 2000 Declaration 
of Helsinki and the Declaration of Istanbul 2008.
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tests
Antibodies were tested with Liaison SARS- CoV- 2 
TrimericS IgG assay (DiaSorin, Saluggia, Italy), 
which uses a recombinant trimeric spike glycopro-
tein as capture antigen with a cutoff value for positiv-
ity of 34 binding antibody units (BAU) per mL; the 
assay range is 5 to 2080 BAU/mL. According to the 
manufacturer, sensitivity and specificity of the test 
are 98.7% and 99.5%, respectively, and the positive 
agreement with the plaque reduction neutralization 
test is 100.0%. Currently, the plaque reduction neu-
tralization test is considered the gold standard for 
detecting and measuring antibodies that can neutral-
ize viruses.
statistical analYsis
Categorical variables are represented as number (per-
centage) and compared using Fisher’s exact test or chi- 
square test. Quantitative variables are shown as median 
(interquartile range [IQR]; 25th– 75th percentiles), and 
their distribution was evaluated with the D’Agostino 
and Pearson test. Parametric data were evaluated 
by t test, and nonparametric data were evaluated by 
Mann- Whitney U test and Wilcoxon matched- pairs 
signed rank test, as appropriate. Spearman rank cor-
relation was used to test correlations between variables. 
P < 0.05 in a 2- tailed test was considered statistically 
significant.
Results
HUMOral iMMUnitY OF Mrna 
vaccinatiOn
At the beginning and at the end of the enrollment 
period, in our center, 76 and 69 adult patients were, 
respectively, on the LT waiting list, and 100 patients 
received transplantations. We enrolled 89 patients 
who completed the anti- SARS- CoV- 2 vaccination 
(93.3% Comirnaty, 6.7% Moderna COVID- 19). A 
total of 79 patients received 2 vaccine doses, and 10 
patients received only 1 dose, as per protocol. The 
median follow- up after completion of the vaccine 
schedule was 110 days (IQR, 98- 122 days). Of the 
patients, 70% lived in Piedmont, and 30.0% in other 
Italian regions. The median age of the pre- LT patients 
and healthy controls was similar: 56 years (IQR, 50- 
62 years) versus 55 years (IQR, 46- 59 years), respec-
tively (P = 0.17), and men were equally represented 
in the 2 groups (69.7% versus 70.0%, respectively; 
P = 0.97). In the study group, the median body mass 
index (BMI) was 24.6 kg/m2, and 48.3% of the pa-
tients had blood type 0. Of the patients, 32.6% were 
affected by viral cirrhosis, 41.6% by HCC, and 77.5% 
by severe portal hypertension. The 2 patients listed 
for autoimmune cirrhosis were treated with low- dose 
steroids. The median Model for End- Stage Liver 
Disease (MELD) score at the time of waitlist reg-
istration was 12 (IQR, 8- 15). A total of 7 patients 
were affected by polycystic liver- kidney disease (4 of 
them on dialysis, and all were listed for simultane-
ous liver- kidney transplantation), and 6 patients had 
polycystic liver disease with massive hepatomegaly, 
taBle 1. characteristics of pretransplant patients (n = 89)
Male 62 (69.7)
Age, years 56 (50- 62)
Body mass index, kg/m2 24.6 (22.3- 27.8)







Etiology of liver disease
Viral cirrhosis 29 (32.6)
Alcohol- related cirrhosis 18 (20.2)
Biliary cirrhosis 10 (11.2)
Dysmetabolic cirrhosis 10 (11.2)
Liver- kidney polycystic disease† 7 (7.9)
Liver polycystic disease 6 (6.7)
Cryptogenic cirrhosis 3 (3.4)
Autoimmune cirrhosis 2 (2.2)
Budd- Chiari cirrhosis 2 (2.2)
Hepatic adenomatosis 2 (2.2)
Hepatocellular carcinoma 37 (41.6)
Severe portal hypertension 69 (77.5)
MELD score at the time of LT waitlist registration 12 (8- 15)
mRNA vaccine
Comirnaty (Pfizer- BioNTech, New York, NY) 83 (93.3)
Moderna (Cambridge, MA) 6 (6.7)
NOTE: Categorical variables are presented as number (%), and 
quantitative variables are presented as median (IQR).
*Cockcroft- Gault equation.
†Patients listed for simultaneous liver- kidney transplantation.
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malnutrition, cholestasis, and portal hypertension 
(Table 1).
The median elapsed time between vaccination and 
IgG test in the pre- LT patients was 23 days (IQR, 14- 
42 days) at T1 and 68 days (IQR, 55- 85 days) at T2, 
whereas the control group underwent an anti- SARS- 
CoV- 2 test 4 months after vaccination (P < 0.01 versus 
T1 and versus T2).
In the study group, the rate of seroconversion at T1 
was 94.4% (84/89), with a median IgG value of 1980 
BAU/mL (IQR, 646- 2080 BAU/mL). The 5 patients 
who tested negative received the Comirnaty vaccine. A 
total of 3 patients were affected by decompensated liver 
disease, with median MELD scores of 19 (range, 18- 
22), 1 patient was treated with steroids because of IgG4 
cholangitis, none of the patients had diabetes mellitus, 
renal failure, or HIV infection (Table 2). Among the 
50 patients who reached T2 of follow- up, 4 remained 
negative, as reported in Table 2, and 46 retested posi-
tive, with a seroconversion rate of 92.0% (46/50) and a 
median IgG titer of 1450 BAU/mL (IQR, 577- 2080 
BAU/mL; T1 versus T2, P = 0.38).
Of 89 patients, 79 received 2 vaccine doses, and 
their median IgG value was 1870 BAU/mL (IQR, 
602- 2080 BAU/mL) at T1 and 1380 BAU/mL (IQR, 
525- 2080 BAU/mL) at T2 (45 retested patients; T1 
versus T2, P = 0.33; Fig. 1A).
Of 79 pre- LT patients, 36 underwent an IgG test 
before vaccination (T0) and at T1 and T2, and their 
median values were 10 BAU/mL (IQR, 10- 23 BAU/
mL), 2080 BAU/mL (IQR, 1027- 2080 BAU/mL), 
and 1505 BAU/mL (IQR, 745- 2080 BAU/mL), 
respectively (T0 versus T1, P < 0.001; T1 versus T2, 
P = 0.11; Fig. 1B).
In 10 of the 89 patients who received only 1 dose 
because of a previous history of COVID- 19 infection, 
the median IgG value was 274 BAU/mL (IQR, 68- 
548 BAU/mL) at T0, 2080 BAU/mL (IQR, 1165- 
2080 BAU/mL) at T1, and 2030 BAU/mL (IQR, 
964- 2080 BAU/mL) at T2 (T0 versus T1, P = 0.03; 
T1 versus T2, P = 0.99).
The median SARS- CoV- 2 IgG values of the 
64 pre- LT patients with compensated liver disease 
(MELD scores <15 at the time of LT waitlist reg-
istration) were not statistically different compared 
with the 25 patients with decompensated liver disease 
(MELD scores ≥15): at T1, 2080 versus 1240 BAU/
mL (P  =  0.12); at T2, 1890 versus 1280 BAU/mL 
(P  =  0.57), respectively. The MELD score did not 
show a correlation with IgG titer (Spearman ranked 
coefficient, r = −0.04, P = 0.87).
All of the participants in the control group devel-
oped IgG anti- SARS CoV- 2, with a median value of 
847 BAU/mL (IQR, 509- 1165 BAU/mL) at 4 months 
after vaccination (P < 0.001 versus T1 and P = 0.04 
versus T2 in the study group).
Of 89 patients, 26 (29.2%) underwent an LT during 
the study period. No organs from executed prisoners 
taBle 2. characteristics of pretransplant patients With Undetectable igg anti- sars- cov- 2 after vaccination
Patients’ characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex Male Female Male Male Male
Age, years 62 57 38 50 42
BMI, kg/m2 28.4 23.0 23.3 21.5 23.7
eGFR, mL/minute 102 76 103 102 105
Etiology of cirrhosis Alcoholic NASH HCV Cryptogenic IgG4 cholangitis Viremic HCV
Severe portal hypertension Yes Yes Yes No Yes
MELD score 19 9 22 6 18
HCC No Yes No No No
Comorbidities Myelofibrosis Giant condyloma Common variable immunodeficiency Silicosis Epilepsy
Therapy Hydroxyurea – Endovenous immunoglobulin Steroids – 
Past COVID- 19 infection No No No No Yes
Comirnaty doses (Pfizer- BioNTech, 
New York, NY)
2 2 2 2 1
IgG anti- SARS- Cov- 2 (BAU/mL)*
T1 12 16 13 5 32
T2 9 9 – 5 18
*Liaison SARS- CoV- 2 TrimericS IgG assay (DiaSorin, Saluggia, Italy); cutoff value for positivity, 34 BAU/mL.
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were used. Before transplant, 84.6% received 2 doses 
of Comirnaty, 3.9% received 2 doses of Moderna, and 
11.5% received 1 dose of Comirnaty because of previ-
ous COVID- 19 infection.
The LT patients underwent immunosuppression with 
steroids, tacrolimus, and mycophenolate mofetil. At the 
end of the study period follow- up, 12 were retested for 
IgG anti- SARS- CoV- 2 at a median time from trans-
plant of 37 days (IQR, 33- 58 days). The median IgG 
titer was 1165 BAU/mL (IQR, 425- 2080 BAU/mL) 
before transplant and dropped to 207 BAU/mL (IQR, 
36- 732 BAU/mL) after the operation (P =  0.04). At 
the end of the study follow- up, none of the patients or 
controls developed COVID- 19 infection.
saFetY
No serious adverse event was reported in the control 
or pre- LT group. In the pre- LT group, 43.8% expe-
rienced pain and swelling at the injection site, 14.6% 
fatigue, 11.2% headache, 13.0% fever, and 3.4% muscle 
and joint pain. In the control group, 43.3% experienced 
Fig. 1. (A) IgG titers anti- SARS- CoV- 2 with median and IQR in pre- LT candidates at baseline (T0, available for 52 patients), after 
completion of 2 vaccine doses at T1 (available for all 79 enrolled patients) and at T2 (available for 45 patients); (T0 versus T1, P < 0.001; 
T1 versus T2, P = 0.33). (B) Individual variations of IgG anti- SARS- CoV- 2 from T0 to T1 and T2 after completion of 2 vaccine doses 
in 36 pre- LT candidates (T0 versus T1, P < 0.001; T1 versus T2, P = 0.11). Liaison SARS- CoV- 2 TrimericS IgG assay (DiaSorin, 
Saluggia, Italy) was used; cutoff value for positivity, 34 BAU/mL.
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pain and swelling at the injection site, 33.3% fatigue, 
30.0% muscle and joint pain, 23.3% headache, 16.7% 
fever, and 3.3% nausea (global P = 0.71; Fig. 2).
Discussion
In our multiregional, monocentric cohort of pa-
tients awaiting LT, the seropositivity rate elicited by 
mRNA vaccination against SARS- CoV- 2 was sur-
prisingly similar to the rate reported in healthy partic-
ipants,(12,16) and none of them developed COVID- 19 
infection after vaccination during a median follow- up 
of 110 days.
In December 2020, the US Food and Drug 
Administration issued emergency use authorization 
for mRNA vaccines developed by Pfizer- BioNTech 
and Moderna, making them the first mRNA vac-
cines available to the public. Vaccines against SARS- 
CoV- 2 showed efficacy in preventing symptomatic 
COVID- 19 and in reducing the length of stay in 
hospital and mortality rates. Despite more than 
200,000 participants enrolled in phase 3 trials, there 
is scarcity of data in patients with CLD.(12,17) The 
number of patients with liver disease enrolled was 
too low to conclude unequivocally regarding safety 
and efficacy. In the Pfizer/BioNTech vaccination 
study, only 3 patients (<0.1%) had moderate to severe 
liver disease,(12) and in the Moderna trial, only 196 
(0.6%) patients with liver disease were included.(17) 
Nevertheless, in view of the higher risk of COVID- 
19– related mortality in patients with CLD, the 
American Association for the Study of Liver(13) 
and the European Association for the Study of the 
Liver(14) recommended prioritization of COVID- 19 
vaccination in patients with advanced liver disease. A 
multicenter Chinese study(18) evaluated the antibody 
response in 381 patients with nonalcoholic fatty 
liver disease at least 14  days after the second dose 
of alum- adjuvanted inactivated COVID- 19 vaccine. 
Of the patients, 95.5% elicited detectable antibody 
response, similar to healthy individuals, and accord-
ing to Cornberg and Eberhardt,(19) the young age of 
the cohort (median age, 39 years) with a low rate of 
Fig. 2. Local and systemic reactions reported by 89 pre- LT patients and 30 healthy controls within 1 month after anti- SARS- CoV- 2 
mRNA vaccination.
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diabetes mellitus (3.7%) might explain the high sero-
positivity rate. At the previous Virtual International 
Liver Congress in 2021, Hakimiah et al.(20) showed 
that among 88 patients with nonalcoholic fatty 
liver disease, 98.9% achieved a good response, but 
advanced fibrosis was correlated with lower IgG 
titers. The authors therefore suggested a third dose 
vaccine booster in those at- risk patients. According 
to current literature, however, we do not know the 
relevance of excellent versus good response to the 
vaccine(20) and antibody thresholds for protection; 
monitoring the incidence of COVID- 19 infection in 
our pre- LT vaccinated patients will clarify this point. 
In our study that enrolled 89 pre- LT patients, with a 
median MELD at registration on the LT list of 12, 
more than half of them with severe portal hyper-
tension and HCC in 41.6%, with a median age of 
56 years, the rate of immunization was similar to the 
data of Wang et al.(18) and healthy participants.(12,17) 
Comparable results have been recently published by 
Thuluvath et al.,(21) who enrolled 79 patients with 
cirrhosis (10 with decompensation) and 92 with 
CLD: 95.9% developed detectable antibody lev-
els after 41 days from the final vaccine dose (91.8% 
mRNA vaccine). Among patients with undetectable 
antibodies, 1 was affected by nonalcoholic steato-
hepatitis (NASH) and 6 by autoimmune hepatitis (2 
with compensated and 1 with decompensated cirrho-
sis, and 5 of 6 were on immunosuppression therapy). 
On multiple logistic regression analysis, immuno-
suppressive status was associated with a poor anti-
body response, whereas cirrhosis did not correlate.
The IgG titer both at T1 and at T2 was higher in 
our pretransplant candidates compared with healthy 
participants, most likely because of the longer interval 
between the IgG test and vaccination in our control 
group. The initial decline of the IgG titer between 
T1 and T2 in our study group seems to support this 
hypothesis; however, ongoing longitudinal assessment 
of antibody titers will add more insight. To date, anti-
body kinetics data after vaccination remain fragmented; 
however, Doria- Rose et al.(22) showed persistence of 
antibodies 6 months after the second dose of mRNA- 
1273 vaccine in 33 healthy adult participants included 
in the phase 1 follow- up of the Moderna study.(17)
With other vaccines, which usually contain inacti-
vated disease- causing organisms or antigens that work 
by mimicking the infectious agent, such as against 
influenza and hepatitis B virus, patients with advanced 
CLD have been shown to elicit lower humoral 
immune response,(10) and vaccine formulation with 
more stimulating adjuvants have been used to improve 
hypo- responsiveness.(23) Our preliminary data suggest 
instead that mRNA vaccination may represent a prom-
ising alternative to conventional vaccine approaches, 
especially in pre- LT patients, even if IgG titers seem 
to significantly drop early after LT, but longer fol-
low- up is needed. This technology has until recently 
been restricted by the instability and inefficient in vivo 
delivery of mRNA. Recent advances have now largely 
overcome these issues, and multiple mRNA vaccine 
platforms against infectious diseases and several types 
of cancer have demonstrated encouraging results in 
both animal models and humans. RNA vaccines are 
not made with pathogen particles or inactivated patho-
gens, so they are noninfectious. RNA does not inte-
grate itself into the host genome, and the RNA strand 
in the vaccine is degraded once the protein is made. 
On the other hand, the mRNA technology allowed 
to achieve seropositivity rate of only 47.5% in another 
study looking at immunosuppressed LT recipients and 
their antibody titers were significantly lower compared 
to healthy controls.(24) For this reason, recent articles 
suggested the administration of a third dose of mRNA 
vaccine to solid organ transplant recipients to signifi-
cantly improve its immunogenicity.(15,16)
Our data and the data of Thuluvath et al.(21) seem 
to support the premise that efforts should be made 
to vaccinate patients on LT waiting list, considering 
the poor outcomes from COVID- 19 in patients with 
cirrhosis and the disappointing post- LT seroconver-
sion rate.(5,14,24) Furthermore, the increasing number 
of vaccinated LT candidates might allow the use of 
precious organs from donors with active COVID- 19 
infection.(25)
The main limitations of this study are the monocen-
tric even if multiregional enrollment, the small number 
of patients, the low median MELD score, the different 
elapsed time between vaccination and IgG tests in the 
pre- LT and control groups, and the lack of long- term 
post- LT follow- up, but we believe that preliminary 
data are necessary to support our ongoing everyday 
policy with very fragile pretransplant candidates.
In conclusion, as we wait for the results from ongo-
ing trials, especially in patients with severe decompen-
sated cirrhosis, our real- life data on 89 candidates listed 
for LT suggest (1) a surprisingly high rate of immuni-
zation that together with mask wearing indoors likely 
confers protection against SARS- CoV- 2 infection; (2) 
a confirmation of the safety of the mRNA COVID- 19 
calleri et al. liver transplantatiOn,  Month 2021
8 | Original article
vaccines, also in very fragile patients, and (3) vaccina-
tion efforts should be encouraged for patients affected 
by liver disease and those on the LT waiting list. 
Persistence of humoral response should be monitored 
over time, in particular after LT, and T cell immunity 
must be explored to better understand the global vac-
cine effect. The growing number of variants that may 
evade individual immunity is 1 of the major challenges 
we now have to face.(26)
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